All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Patient case discussion on treating with CELMoDs
Featured:
Paul Richardson
Elena Zamagni
Hermann Einsele
Morie Gertz
Heinz Ludwig
Sagar Lonial
María-Victoria Mateos
Meral BeksaçDuring the Multiple Myeloma Hub Steering Committee Meeting in November 2023, key opinion leaders met to discuss patient cases on treatment with Cereblon E3 ligase modulator (CELMoDs). This recorded discussion was chaired by Paul Richardson and featured Sagar Lonial, María-Victoria Mateos, Heinz Ludwig, Hermann Einsele, Morie Gertz, Elena Zamagni, and Meral Beksac.
Patient case discussion on treating with CELMoDs
This session opened with a presentation from Paul Richardson in which they shared the mechanism of action, latest clinical data, and applications for CELMoDs in multiple myeloma. Richardson highlighted iberdomide and mezigdomide as novel agents and discussed the latest data from trials on their use both as monotherapies and in combination.
The panel discussed differences between the two agents, the incorporation of these drugs into the myeloma treatment landscape, and optimal combination treatments. The experts concluded by discussing the incidence of secondary malignancies associated with these agents and the applications of CELMoDs in extramedullary multiple myeloma.
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?
